These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 26050527)

  • 21. Interactions of the natural product kendomycin and the 20S proteasome.
    Beck P; Heinemeyer W; Späth AL; Elnakady Y; Müller R; Groll M
    J Mol Biol; 2014 Sep; 426(18):3108-3117. PubMed ID: 25038530
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genetic basis for the biosynthesis of the pharmaceutically important class of epoxyketone proteasome inhibitors.
    Schorn M; Zettler J; Noel JP; Dorrestein PC; Moore BS; Kaysser L
    ACS Chem Biol; 2014 Jan; 9(1):301-9. PubMed ID: 24168704
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Design, synthesis and biological evaluation of peptidyl epoxyketone proteasome inhibitors composed of β-amino acids.
    Zhang J; Han M; Ma X; Xu L; Cao J; Zhou Y; Li J; Liu T; Hu Y
    Chem Biol Drug Des; 2014 Nov; 84(5):497-504. PubMed ID: 24751157
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development of peptidomimetic boronates as proteasome inhibitors.
    Micale N; Ettari R; Lavecchia A; Di Giovanni C; Scarbaci K; Troiano V; Grasso S; Novellino E; Schirmeister T; Zappalà M
    Eur J Med Chem; 2013 Jun; 64():23-34. PubMed ID: 23639651
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discovery of novel 20S proteasome inhibitors by rational topology-based scaffold hopping of bortezomib.
    Xu Y; Yang X; Chen Y; Chen H; Sun H; Li W; Xie Q; Yu L; Shao L
    Bioorg Med Chem Lett; 2018 Jul; 28(12):2148-2152. PubMed ID: 29773504
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Structural Basis for the Species-Selective Binding of N,C-Capped Dipeptides to the Mycobacterium tuberculosis Proteasome.
    Hsu HC; Singh PK; Fan H; Wang R; Sukenick G; Nathan C; Lin G; Li H
    Biochemistry; 2017 Jan; 56(1):324-333. PubMed ID: 27976853
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Blockade of the malignant phenotype by β-subunit selective noncovalent inhibition of immuno- and constitutive proteasomes.
    Villoutreix BO; Khatib AM; Cheng Y; Miteva MA; Maréchal X; Vidal J; Reboud-Ravaux M
    Oncotarget; 2017 Feb; 8(6):10437-10449. PubMed ID: 28060729
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development of novel selective peptidomimetics containing a boronic acid moiety, targeting the 20S proteasome as anticancer agents.
    Scarbaci K; Troiano V; Ettari R; Pinto A; Micale N; Di Giovanni C; Cerchia C; Schirmeister T; Novellino E; Lavecchia A; Zappalà M; Grasso S
    ChemMedChem; 2014 Aug; 9(8):1801-16. PubMed ID: 24891205
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bisbenzimidazole derivatives as potent inhibitors of the trypsin-like sites of the immunoproteasome core particle.
    Koroleva ON; Pham TH; Bouvier D; Dufau L; Qin L; Reboud-Ravaux M; Ivanov AA; Zhuze AL; Gromova ES; Bouvier-Durand M
    Biochimie; 2015 Jan; 108():94-100. PubMed ID: 25446655
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Terminal functionalized thiourea-containing dipeptides as multidrug-resistance reversers that target 20S proteasome and cell proliferation.
    Qin JM; Huang RZ; Yao GY; Liao ZX; Pan YM; Wang HS
    Eur J Med Chem; 2017 Jan; 126():259-269. PubMed ID: 27889629
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synthesis, bioactivity, docking and molecular dynamics studies of furan-based peptides as 20S proteasome inhibitors.
    Sun Q; Xu B; Niu Y; Xu F; Liang L; Wang C; Yu J; Yan G; Wang W; Jin H; Xu P
    ChemMedChem; 2015 Mar; 10(3):498-510. PubMed ID: 25641789
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development of Macrocyclic Peptides Containing Epoxyketone with Oral Availability as Proteasome Inhibitors.
    Li D; Zhang X; Ma X; Xu L; Yu J; Gao L; Hu X; Zhang J; Dong X; Li J; Liu T; Zhou Y; Hu Y
    J Med Chem; 2018 Oct; 61(20):9177-9204. PubMed ID: 30265557
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Structure-based design of β1i or β5i specific inhibitors of human immunoproteasomes.
    de Bruin G; Huber EM; Xin BT; van Rooden EJ; Al-Ayed K; Kim KB; Kisselev AF; Driessen C; van der Stelt M; van der Marel GA; Groll M; Overkleeft HS
    J Med Chem; 2014 Jul; 57(14):6197-209. PubMed ID: 25006746
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A mass spectrometry platform for a streamlined investigation of proteasome integrity, posttranslational modifications, and inhibitor binding.
    Gersch M; Hackl MW; Dubiella C; Dobrinevski A; Groll M; Sieber SA
    Chem Biol; 2015 Mar; 22(3):404-11. PubMed ID: 25728267
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 20S proteasome as novel biological target for organochalcogenanes.
    Piovan L; Milani P; Silva MS; Moraes PG; Demasi M; Andrade LH
    Eur J Med Chem; 2014 Feb; 73():280-5. PubMed ID: 24463395
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Minimal β-Lactone Fragment for Selective β5c or β5i Proteasome Inhibitors.
    Groll M; Korotkov VS; Huber EM; de Meijere A; Ludwig A
    Angew Chem Int Ed Engl; 2015 Jun; 54(27):7810-4. PubMed ID: 25973989
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular modeling on porphyrin derivatives as β5 subunit inhibitor of 20S proteasome.
    Arba M; Nur-Hidayat A; Ruslin ; Yusuf M; Sumarlin ; Hertadi R; Wahyudi ST; Surantaadmaja SI; Tjahjono DH
    Comput Biol Chem; 2018 Jun; 74():230-238. PubMed ID: 29674291
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Flavin-Dependent Decarboxylase-Dehydrogenase-Monooxygenase Assembles the Warhead of α,β-Epoxyketone Proteasome Inhibitors.
    Zabala D; Cartwright JW; Roberts DM; Law BJ; Song L; Samborskyy M; Leadlay PF; Micklefield J; Challis GL
    J Am Chem Soc; 2016 Apr; 138(13):4342-5. PubMed ID: 26999044
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel beta-lactam derivatives: potent and selective inhibitors of the chymotrypsin-like activity of the human 20S proteasome.
    Imbach P; Lang M; García-Echeverría C; Guagnano V; Noorani M; Roesel J; Bitsch F; Rihs G; Furet P
    Bioorg Med Chem Lett; 2007 Jan; 17(2):358-62. PubMed ID: 17095212
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Optimization of peptidomimetic boronates bearing a P3 bicyclic scaffold as proteasome inhibitors.
    Troiano V; Scarbaci K; Ettari R; Micale N; Cerchia C; Pinto A; Schirmeister T; Novellino E; Grasso S; Lavecchia A; Zappalà M
    Eur J Med Chem; 2014 Aug; 83():1-14. PubMed ID: 24946214
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.